Home | Welcome to Contract Pharma   
Last Updated Monday, October 20 2014
Print

Genmab, Lilly Enter DuoBody Platform Pact



By Kristin Brooks



Published January 14, 2014
Genmab has entered a research collaboration with Eli Lilly and Co. for the use Genmab's DuoBody technology platform to create bispecific antibodies. Lilly will initially evaluate the DuoBody technology platform in house. Financial terms were not disclosed. 
 
Jan van de Winkel, Ph.D., chief executive officer of Genmab, commented, “Our DuoBody platform continues to attract strong interest from the pharmaceutical industry and we are pleased to enter our fifth partnership for this innovative bispecific antibody technology. Under this new collaboration, Lilly will evaluate the capabilities and strengths of our DuoBody platform and may consider entering a commercial license agreement if the evaluation is successful.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On